Parents across the U.S. are scrambling to find baby formula because supply disruptions and a massive safety recall have swept many leading brands off store shelves.
Months of spot shortages at pharmacies and supermarkets have been exacerbated by the recall at Abbott, which was forced to shutter its largest U.S. formula manufacturing plant in February due to contamination concerns.
On Monday, White House press secretary Jenn Psaki said the Food and Drug Administration was “working around the clock to address any possible shortages" and will try to expedite imports of foreign baby formula to increase supply.
For now, pediatricians and health workers are urging parents who can’t find formula to contact food banks or doctor's offices. They warn against watering down formula to stretch supplies or using online DIY recipes.
“For babies who are not being breastfed, this is the only thing they eat," said Dr. Steven Abrams, of the University of Texas, Austin. "So it has to have all of their nutrition and, furthermore, it needs to be properly prepared so that it’s safe for the smallest infants.”
Laura Stewart, a 52-year-old mother of three who lives just north of Springfield, Missouri, has been struggling for several weeks to find formula for her 10-month-old daughter, Riley.
Riley normally gets a brand of Abbott's Similac designed for children with sensitive stomachs. Last month, she instead used four different brands.
“She spits up more. She’s just more cranky. She is typically a very happy girl," Hughes said. "When she has the right formula, she doesn’t spit up. She’s perfectly fine."
A small can costs $17 to $18 and lasts three to five days, Stewart said.
Like many Americans, Hughes relies on WIC — a federal program similar to food stamps that serves mothers and children — to afford formula for her daughter. Abbott's recall wiped out many WIC-covered brands, though the program is now allowing substitutions.
Trying to keep formula in stock, retailers including CVS and Walgreens have begun limiting purchases to three containers per customer.
Nationwide about 40% of big box stores are out of stock, up from 31% in mid-April, according to Datasembly, a data analytics firm. More than half of U.S. states are seeing out-of-stock rates between 40% and 50%, according to the firm, which collects data from 11,000 locations.
Baby formula is particularly vulnerable to disruptions because just a handful of companies account for almost the entire U.S. supply.
Industry executives say the constraints began last year as the COVID-19 pandemic led to disruptions in ingredients, labor and transportation. Supplies were further squeezed by parents stockpiling during lockdowns.
Then in February, Abbott recalled several major brands and shut down its Sturgis, Michigan, factory when federal officials concluded four babies suffered bacterial infections after consuming formula from the facility. Two of the infants died.
When FDA inspectors visited the plant in March they found lax safety protocols and traces of the bacteria on several surfaces. None of the bacterial strains matched those collected from the infants, however, and the FDA hasn’t offered an explanation for how the contamination occurred.
For its part, Abbott says its formula “is not likely the source of infection,” though the FDA says its investigation continues.
The shortages are especially dangerous for infants who require specialty formulas due to food allergies, digestive problems and other conditions.
“Unfortunately, many of those very specialized formulas are only made in the United States at the factory that had the recall, and that's caused a huge problem for a relatively small number of infants," Abrams said.
After hearing concerns from parents, the FDA said last month that Abbott could begin releasing some specialty formulas not affected by the recalls “on a case-by-case basis." The company is providing them free of charge, in coordination with physicians and hospitals.
Food safety advocates say the FDA made the right call in releasing the formula, but that parents should talk to their pediatricians before using it.
“There’s still some risk from the formula because we know there are problems at the plant and FDA hasn’t identified a root cause,” said Sarah Sorscher of the Center for Science in the Public Interest. ”But it’s worth releasing because these infants might die without it."
It’s unclear when the Abbott plant might reopen.
An FDA spokeswoman said the company is still working "to rectify findings related to the processes, procedures, and conditions.” The agency also is working with other manufacturers to consider options for increasing production.
Industry professionals say it will be hard to boost supply quickly, because the FDA requires extensive testing, labeling and inspections.
“It’s a long and rigorous process to bring any new manufacturers into this country,” said Ron Belldegrun, co-founder of ByHeart, a New York-based specialty formula maker that recently launched its first product after four years in development.
___
Hollingsworth reported from Kansas City, Missouri.
___
Follow Matthew Perrone on Twitter: @AP_FDAwriter
